None listed
Conditions
Brief summary
Postprandial hypotension (PPH) is defined as a larger than expected fall in blood pressure following a meal – the more exact definition is a fall in blood pressure of greater than 20mmHg for a period lasting longer than 30 minutes, following a meal. PPH may lead to fainting and is common in older people. In this study, we are interested in seeing whether a preload containing whey protein and guar (Omniblend) can reduce the fall in blood pressure after a sugary drink – and also whether the rate of stomach emptying is affected by this preload.
Interventions
Subjects will participate in two separate occasions at least five days apart after fasting from solids for 14 h and liquids for 12 h. Subjects will receive a phone call the day before the study to remind them of the requirement to fast and this will also be queried on the morning of the study.
After a rest-period of 15-30 minutes to allow baseline BP to settle, subjects will be given: in random order, either:
(i) a test drink containing 50 g glucose labelled with 20 MBq 99mTc-calcium phytate, ma
Subjects will participate in two separate occasions at least five days apart after fasting from solids for 14 h and liquids for 12 h. Subjects will receive a phone call the day before the study to remind them of the requirement to fast and this will also be queried on the morning of the study. After a rest-period of 15-30 minutes to allow baseline BP to settle, subjects will be given: in random order, either: (i) a test drink containing 50 g glucose labelled with 20 MBq 99mTc-calcium phytate, made up to 300ml water (ii) a preload containing 20g whey protein and 5g guar (Omniblend) made up to 150ml with water 15 minutes before the ingestion of the test drink. Subjects will undergo concurrent measurements of gastrointestinal (GI) symptoms (questionnaire), gastric emptying (scintigraphy), blood pressure, heart rate (DINAMAP), superior mesenteric artery blood flow (Doppler ultrasound), blood glucose, serum insulin, plasma Glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP) and glucose absorption (utilising 3-OMG).
Sponsors
Professor Karen Jones
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
• Healthy subjects • Body Mass Index 19-30 kg/m²
Exclusion criteria
• History of diabetes mellitus (or fasting plasma glucose =7.0 mmol/L or HbA1C =6.5%) • Severe respiratory or cardiovascular disease which would limit tolerance of study • Hepatic disease as defined by transaminases more than 2 x upper limit of normal or bilirubin more than 2 X upper limit of normal • Renal disease (creatinine clearance less than 50 mL/min) • Anaemia or iron deficiency
Outcome results
None listed